These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21299161)

  • 21. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS testing on colo-rectal carcinoma cytological imprints.
    Malapelle U; Bellevicine C; Russo A; Salatiello M; Palombini L; Troncone G
    Diagn Cytopathol; 2011 Apr; 39(4):274-7. PubMed ID: 20607679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
    Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
    Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
    de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
    J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
    [No Abstract]   [Full Text] [Related]  

  • 25. Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.
    Chu E
    Oncology (Williston Park); 2014 Feb; 28(2):96. PubMed ID: 24701695
    [No Abstract]   [Full Text] [Related]  

  • 26. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.
    Deans ZC; Tull J; Beighton G; Abbs S; Robinson DO; Butler R
    Genet Test Mol Biomarkers; 2011 Nov; 15(11):777-83. PubMed ID: 21851273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Validation study of KRAS mutation in colorectal cancer].
    Kopper L; Tímár J
    Magy Onkol; 2009 Dec; 53(4):361-6. PubMed ID: 20071308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
    Garassino MC; Farina G; Rossi A; Martelli O; Torri V
    J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
    [No Abstract]   [Full Text] [Related]  

  • 30. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
    Jimeno A; Messersmith WA; Hirsch FR; Franklin WA; Eckhardt SG
    J Clin Oncol; 2009 Mar; 27(7):1130-6. PubMed ID: 19124802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.
    Jimeno A; Messersmith WA; Hirsch FR; Franklin WA; Eckhardt SG
    Cancer J; 2009; 15(2):110-3. PubMed ID: 19390304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers.
    Dudley J; Tseng LH; Rooper L; Harris M; Haley L; Chen G; Gocke CD; Eshleman JR; Lin MT
    Arch Pathol Lab Med; 2015 Feb; 139(2):211-8. PubMed ID: 25611103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.
    Okayama N; Nishioka M; Hazama S; Sakai K; Suehiro Y; Maekawa M; Sakamoto J; Iwamoto S; Kato T; Mishima H; Oka M; Hinoda Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):165-71. PubMed ID: 20926413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
    Russo A; Rizzo S; Bronte G; Silvestris N; Colucci G; Gebbia N; Bazan V; Fulfaro F
    Oncology; 2009; 77 Suppl 1():57-68. PubMed ID: 20130433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
    Enlund F; Helenius G; Palmqvist R; Edsjö A; Sundström M
    Lakartidningen; 2010 Feb 3-9; 107(5):255-9. PubMed ID: 20297566
    [No Abstract]   [Full Text] [Related]  

  • 36. KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.
    Bekaii-Saab T
    Clin Colorectal Cancer; 2009 Jul; 8(3):135-40. PubMed ID: 19632927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
    Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
    Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
    Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
    Jacobs B; De Roock W; Piessevaux H; Van Oirbeek R; Biesmans B; De Schutter J; Fieuws S; Vandesompele J; Peeters M; Van Laethem JL; Humblet Y; Pénault-Llorca F; De Hertogh G; Laurent-Puig P; Van Cutsem E; Tejpar S
    J Clin Oncol; 2009 Oct; 27(30):5068-74. PubMed ID: 19738126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.
    Domagała P; Hybiak J; Sulżyc-Bielicka V; Cybulski C; Ryś J; Domagała W
    Pol J Pathol; 2012 Nov; 63(3):145-64. PubMed ID: 23161231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.